Listen to this article
Estimated 4 minutes
The audio version of this article is generated by AI‑based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results.
Aurora Cannabis Considers Unsolicited Takeover Bid from Curaleaf
On Tuesday, Aurora Cannabis Inc. announced the formation of a special committee to evaluate an unsolicited acquisition proposal from U.S.–based Curaleaf Holdings Inc. The move follows Curaleaf’s public disclosure that it had prepared a purchase offer for all of Aurora’s shares after private negotiations failed to progress.
Background of the Offer
Curaleaf, headquartered in Stamford, Connecticut and listed on the Toronto Stock Exchange, said it sent a formal letter of intent to Aurora’s board on June 23, outlining a proposal to buy the Edmonton‑based cannabis producer. A follow‑up letter arrived on July 7, but Aurora’s board reportedly declined to engage in substantive discussions.
Boris Jordan, Curaleaf’s chief executive, expressed disappointment in a press release, stating that the company would now take its proposal directly to Aurora shareholders because the offered premium is significant and further delay is unjustified. He added that Curaleaf remains ready to work constructively with Aurora’s board to reach a definitive agreement.
Details of the Proposed Deal
According to Curaleaf’s disclosure, the offer consists of US $4.00 in cash for each Aurora share, plus an additional US $0.75 in cash per share. If accepted, the transaction would create a combined cannabis enterprise operating in 17 countries across Europe, North America and other international markets.
The two companies together generated more than US $1.5 billion in revenue over the past twelve months. Curaleaf estimates that the merger could yield at least US $40 million in annual cost synergies.
Aurora’s Response and Next Steps
Aurora confirmed receipt of the June 23 and July 7 letters, noting that only the July 7 communication contained any financial terms, though it did not specify the cash‑share mix Curaleaf later described. The company denied Curaleaf’s claim that it refused to engage, pointing to correspondence between Aurora’s lead independent director and Curaleaf’s CEO as recently as July 24, in which Aurora indicated it was focused on executing its business plan while remaining open to dialogue.
In response to the unsolicited bid, Aurora’s board has established a special committee of independent directors to assess whether the proposal aligns with the best interests of shareholders and other stakeholders. The company cautioned that there is no guarantee a deal will be reached and that it will continue normal operations in the interim.
Analyst Perspective
TD Cowen analysts Derek Lessard and Ryan Neal published a note on Tuesday suggesting that Curaleaf’s offer undervalues Aurora’s long‑term potential. They argued that the proposed consideration does not fully capture Aurora’s intrinsic value, citing its leadership in medical cannabis, high‑quality product portfolio, strong balance sheet, and proven ability to navigate complex international regulatory environments.
The analysts believe Aurora is positioned to create significantly greater shareholder value over time, independent of a takeover.
Curaleaf’s Strategic Rationale
Jordan said that combining Curaleaf’s global distribution platform with Aurora’s leading international medical cannabis franchise, cultivation capacity and manufacturing capabilities would unlock value for both sets of shareholders. He highlighted that the combined entity would give Aurora investors increased exposure to U.S. regulatory tailwinds and a more diversified global platform.
For readers seeking the original reporting, see the source: Here
